Legislation requiring the federal government to negotiate with the pharmaceutical industry for lower Medicare Part D drug prices could backfire on the program, officials from the Centers for Medicare & Medicaid Services (CMS) warned Congress.
The bill, a key plank in this year's legislative agenda being pushed by congressional Democrats, would not generate any savings at all, testified actuaries from CMS. "Although the bill would require the secretary [of Health and Human Services] to negotiate with drug manufacturers regarding drug prices, the inability to drive market share via the establishment of a formulary or the development of a preferred tier significantly undermines the effectiveness of this negotiation," said Paul Spitalnic, director of the Parts C and D Actuarial Group in the Office of the Actuary. "Manufacturers would have little to gain by offering rebates that aren't linked to a preferred position of their products, and we assume that they will be unwilling to do so."
A separate report issued by researchers at the Government Accountability Office stopped short of predicting failure. It did, however, raise questions about the feasibility of the plan.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs